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Abstract
Matrix metalloproteinase-9 is elevated within the acutely injured murine spinal cord and blockade of this early proteolytic
activity with GM6001, a broad-spectrum matrix metalloproteinase inhibitor, results in improved recovery after spinal cord
injury. As matrix metalloproteinase-9 is likewise acutely elevated in dogs with naturally occurring spinal cord injuries, we
evaluated efficacy of GM6001 solubilized in dimethyl sulfoxide in this second species. Safety and pharmacokinetic studies
were conducted in naı¨ve dogs. After confirming safety, subsequent pharmacokinetic analyses demonstrated that a 100 mg/
kg subcutaneous dose of GM6001 resulted in plasma concentrations that peaked shortly after administration and were
sustained for at least 4 days at levels that produced robust in vitro inhibition of matrix metalloproteinase-9. A randomized,
blinded, placebo-controlled study was then conducted to assess efficacy of GM6001 given within 48 hours of spinal cord
injury. Dogs were enrolled in 3 groups: GM6001 dissolved in dimethyl sulfoxide (n = 35), dimethyl sulfoxide (n = 37), or saline
(n = 41). Matrix metalloproteinase activity was increased in the serum of injured dogs and GM6001 reduced this serum
protease activity compared to the other two groups. To assess recovery, dogs were a priori stratified into a severely injured
group and a mild-to-moderate injured group, using a Modified Frankel Scale. The Texas Spinal Cord Injury Score was then
used to assess long-term motor/sensory function. In dogs with severe spinal cord injuries, those treated with saline had a
mean motor score of 2 (95% CI 0–4.0) that was significantly (P,0.05; generalized linear model) less than the estimated mean
motor score for dogs receiving dimethyl sulfoxide (mean, 5; 95% CI 2.0–8.0) or GM6001 (mean, 5; 95% CI 2.0–8.0). As there
was no independent effect of GM6001, we attribute improved neurological outcomes to dimethyl sulfoxide, a pleotropic
agent that may target diverse secondary pathogenic events that emerge in the acutely injured cord.
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Introduction
Matrix metalloproteinases (MMPs) are endopeptidases that
degrade the extracellular matrix [1]. Several members of the
MMP family, including MMP-9 (gelatinase B) and MMP-12, have
been implicated in early secondary pathogenesis after spinal cord
injury (SCI) [2–4]. These MMPs are released by local cells as well
as by infiltrating leukocytes and result in reduced cell-cell
adhesion, disruption of the blood-spinal cord barrier, up-regula-
tion of pro-inflammatory cytokines, and demyelination [1,4,5].
Early blockade of MMPs confers neuroprotection after SCI
[2,6,7]. Short-term administration of the broad-spectrum MMP
inhibitor, GM6001, results in sparing of white matter and
improves locomotor function when the drug is given over the
first 3 days post-injury [2]. Several lines of evidence suggest that
one likely target of GM6001 is MMP-9. This protease is not
actively expressed in the uninjured spinal cord and is up-regulated
over the first 3 days post-injury, corresponding to the time-course
for infiltration of neutrophils [8]. While there are local sources of
MMP-9, including glia and endothelial cells, neutrophil depletion
studies confirm that these leukocytes are the major source of
MMP-9 in the acutely injured cord [7]. As this protease is not
complexed with tissue inhibitor of MMP-1, degranulation of
neutrophils results in release of activated MMP-9 [9], which then
may disrupt the barrier and facilitate transmigration of leukocytes
into the injured spinal cord. It thus is not surprising that early
administration of GM6001 attenuates the trafficking of neutrophils
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into the injured spinal cord and stabilizes the blood-spinal cord
barrier [2]. There are other members of the MMP family that are
also determinants of recovery after SCI including MMP-12 and
ADAM-8 (a disintegrin and metalloprotease domain) [3]. Thus,
broad inhibitors of MMPs may offer greater benefit than specific
inhibitors of these proteases.
In this study, we have used dimethyl sulfoxide (DMSO) in
combination with GM6001 [10,11]. While DMSO is commonly
used as a vehicle to increase solubility of a drug, it has been
reported to have neuroprotective properties in traumatic brain
injury and SCI [12,13]. The putative neuroprotective activity of
DMSO is thought to arise from its ability to block voltage-sensitive
sodium channels and calcium influx into cells, and mitigate
opening of ionotropic channels that are activated by glutamate
[14].
Few studies have considered a pre-clinical platform involving
dogs with naturally occurring SCIs resulting from intervertebral
disk herniation (IVDH) [15–17]. This approach mimics pathologic
aspects of human SCI including compressive/contusive injuries
and a pro-inflammatory response that includes the infiltration of
neutrophils and up-regulation of MMP-9 [18–20]. Moreover,
these naturally-occurring injuries provide a means for studying
therapeutics in the challenging context of varying degrees of injury
severity, common in human SCI, but without confounding factors
such as anesthetics that are necessary during creation of injury in
experimental models.
Here we evaluate the efficacy of GM6001 in dogs with IVDH.
Based on a double-blind, randomized, placebo-controlled trial,
consisting of 3 groups (GM6001 in DMSO, DMSO alone, or
saline) we show enhanced neurological recovery in dogs sustaining
severe SCIs when treated acutely with GM6001 solubilized in
DMSO or DMSO alone, relative to the saline group. Such
findings implicate DMSO in improving neurological recovery,
which is consistent with its reported ability to attenuate secondary
pathogenic events in various models of neurotrauma [14].
Materials and Methods
Study Design and Inclusion Criteria
A preliminary drug tolerance study was constructed based on
Food and Drug Administration guidelines (http://www.fda.gov/
AnimalVeterinary/default.htm) and performed in 4 healthy,
purpose-bred Beagles. Ten healthy, purpose-bred Beagles were
obtained to evaluate pharmacokinetics (PK); this sample size was
based on similar animal studies and general recommendations for
canine PK investigations [21].
Guidelines for the conduct of SCI trials developed by the
International Campaign for Cures of Spinal Cord Injury Paralysis
were utilized to assist with the design of a randomized, double-
blinded (clinicians and clients were unaware of treatment group),
placebo-controlled canine trial including inclusion/exclusion
criteria, randomization protocol, data handling, and the a priori
definition of outcome metrics and statistical approaches.[22].
Consolidated Standards of Reporting Trials (CONSORT) State-
ment Guidelines were used to assist with trial performance and
data reporting [23,24]. Client-owned dogs with IVDH-associated
SCI, admitted to the Texas A&M University Veterinary Medical
Teaching Hospital between September 2008 and February 2012,
were recruited. The study interval was selected to generate a
sample size of .100 dogs, which was considered robust based on
previous human phase II and III SCI studies [25,26], animal
model studies of SCI using MMP blockers [2], and completed
canine SCI studies [27,28]. A formal power calculation was not
performed due to the absence of a phase I canine study examining
the effects of GM6001.
Dogs had to meet the following criteria to be included in the
clinical trial population: 1) duration of SCI was required to be#48
hours; 2) IVDH-associated SCI had to result in non-ambulatory
paraparesis or paraplegia at enrollment; 3) IVDH-associated SCI
had to be identified between the T8-L6 vertebral articulations and
treated via surgical decompression. The exclusion criteria were: 1)
concurrent disseminated neoplasia or systemic inflammation; 2) a
history of recent breeding/pregnancy; and, 3) glucocorticoid
treatment within 7 days of SCI.
The primary outcome of the clinical trial was a validated ordinal
SCI score (the Texas Spinal Cord Injury Score [TSCIS])
conducted at 42 days post-injury [29]. The secondary outcome
was TSCIS at 3 days after SCI. Dogs were stratified into those
with behaviorally severe SCI (absent pelvic limb movement and
deep nociception) and those with mild-to-moderate SCI (intact
pelvic limb deep nociception with or without movement) at study
entry to examine primary and secondary outcomes. This a priori
stratification was utilized because a substantially lower proportion
of dogs with severe SCI recover independent ambulation at long-
term follow-up time-points (approximately 50–60%) in compari-
son to dogs with mild-to-moderate SCI (approximately 85 to
95%); thus, injury severity might influence the ability to detect
treatment-related effects [30–33].
Ethics Statement
All animal procedures were approved by the Texas A&M
University Institutional Animal Care and Use Committee (AUP
2007–115; AUP 2011–057; AUP-2011–145) and in the case of
client-owned dogs were performed with signed consent. All studies
adhered to the National Institutes of Health Guide for the Care
and Use of Laboratory Animals.
Drug Preparation, Drug Tolerance, and Pharmacokinetic
Procedures
For all canine studies, GM6001 (SAI Advantium, Hyderabad,
India) was dissolved in 90% DMSO (Domoso, Fort Dodge Corp,
Fort Dodge, IA) at a concentration of 250 mg/mL. The solution
was sterilized using a 25-mm syringe filter with 0.22-mm HT
Tuffryn membrane (Pall Corporation, East Hills, NY).
Dogs, participating in the drug tolerance study, were acclima-
tized for 14 days and then randomized as follows: DMSO (at a
volume equivalent to that present in a 100 mg/kg GM6001
treatment), 100 mg/kg GM6001, 150 mg/kg GM6001, or
300 mg/kg GM6001 subcutaneously (SC) every 12 hours for 3
days. The doses of GM6001 were selected to exceed those
reported previously in a murine model of SCI [2]. A SC route of
administration was selected as 1) GM6001 does not remain
solubilized in DMSO when exposed to hydrophilic solutions such
as blood, prohibiting intravenous delivery and 2) intraperitoneal
drug administration is not generally permitted in client-owned
dogs at our institution, due to challenges in managing any local
drug reactions. Adverse event monitoring was performed for 7
days following the completion of drug administration. All dogs had
physical examinations, injection site evaluations, and assessment of
food and water intake twice daily. A complete blood count, serum
biochemistry profile, urinalysis, and coagulation profile were
performed 3 and 7 days following the completion of drug
administration. Following the completion of this study, the vehicle
and 300 mg/kg GM6001 dogs were euthanized via intravenous
administration of 120 mg/kg pentobarbital (Fatal Plus, Vortech
Pharmaceuticals, Dearborn, MI). The brain, heart, liver, kidney,
lung, intestine, and injection sites were evaluated.
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For PK assessments, a single 100 mg/kg SC administration of
GM6001 was delivered in 5 dogs with 5 additional dogs receiving
a second 100 mg/kg SC of GM6001, 12 hours following the first
dose. In dogs with single dosing, serial plasma samples were
obtained at 5, 15, and 30 minutes and 1, 2, 3, 6, 12, 24, 36, 48,
and 96 hours after GM6001 delivery. In dogs with multiple dosing,
blood samples were collected shortly after the second dose, and
then at 24, 48, 72, and 96 hours. All samples were stored in a 2
80oC freezer until analyzed by high performance chromatography
(Thermo Electron Co., Waltham, MA) and tandem mass
spectroscopy (MDS-Sciex/Applied Biosystems API3000, Concord,
ONT) (LC-MS/MS). Concentrations of GM6001 (m/z
389.0R356.0) were determined, using MMP Inhibitor III (m/z
364.0R356.0, Calbiochem, Billerica, MA) as the internal
standard. A standard curve was created with blank dog plasma
at concentrations 10.0 to 10,204.0 ng/mL, with linear regression
and weighting of concentrations (1/x2). After thawing and addition
of internal standard (300 mL of 100 ng/mL in 0.5% acetic acid in
methanol), plasma samples or standards (100 mL) were centrifuged
and reconstituted with 30/70 methanol/10 mM ammonium
formate buffer, pH 3.0, for protein precipitation. Supernatant
(100 mL) was collected, vortexed, and refrigerated until injection
on LC-MS/MS. The mobile phase consisted of 0.1% formic acid
in deionized water (A) and acetonitrile/methanol/formic acid
(40:60:0.1, v/v/v) (B) with a flow rate of 0.30 mL/minute using a
linear gradient starting at 40% B from 0 to 0.01 minutes, to 80% B
at 1.5 minutes, to 90% B at 3.5 minutes, to 40% B at 3.6 minutes,
with a total run time of 5 minutes.
Randomized, Placebo Controlled Study in Dogs with
IVDH-associated SCI
Dogs, enrolled in the clinical trial, had physical and neurological
examinations, complete blood count and serum biochemistry
profile. Anesthesia was induced with propofol (Rapinovet,
Schering-Plough Animal Health Corp, Union, NJ) and maintained
with inhalant sevoflurane (SevoFlo, Abbott Laboratories, North
Chicago, IL). Diagnostic imaging consisting of myelography,
computed tomography (CT), or MRI was performed to identify
IVDH. Cerebrospinal fluid (CSF) was collected from the cisterna
magna for routine analysis and a 200-mL aliquot was stored at 2
80oC for determination of MMP-2/MMP-9 activity. Six mL of
whole blood were obtained at the time of CSF collection and 3
days following treatment delivery; serum was isolated and frozen
at 280oC.
Immediately after collection of CSF and blood, dogs were
randomized to receive 100 mg/kg GM6001+ DMSO, DMSO, or
saline placebo. The dose of both DMSO and saline was 0.4 mL/
kg, a volume equivalent to that of 100 mg/kg GM6001+DMSO;
this approach was taken to maintain blinding. A randomization
sequence was developed prior to the initiation of this trial and
randomization was accomplished by blocking the dogs by gender
status in a 1:1:1 ratio to each of the treatment groups. Sealed
envelopes contained treatment allocations and were delivered to a
central location where treatments were formulated by individuals
not involved in the assessment of animals. Treatments were
covered and marked only with animal identifiers to ensure
blinding.
Following surgical decompression, all dogs were recovered in an
intensive care unit for 24 hours and during that time were
provided post-operative opioid analgesia and bladder evacuation.
Physical rehabilitation protocols were standardized for dogs
participating in this study. Dogs received thoracic limb and pelvic
limb passive range of motion exercises beginning 24 hours post-
operatively and until dogs could independently ambulate. Each
limb was gently flexed and extended at the carpal, elbow, and hip
joints in 3 sets of 10 repetitions, 2 times daily. Supported standing
exercises were performed twice daily for 5 minutes by placing a
sling immediately cranial to the pelvic limbs and continued until
dogs could independently ambulate. Dogs that were non-
ambulatory were walked using a sling placed immediately cranial
to the pelvic limbs for 5 minutes twice daily. Independently
ambulatory dogs were permitted to walk on a leash for 5 minutes
3–4 times per day during hospitalization and were allowed to
continue this activity until 42-day re-check. Participating dogs
were housed in cages that permitted limited additional activity
until 42-day re-check evaluation.
Neurological Assessments
Clinicians responsible for neurologic scoring were blinded to
treatment assignments. Two ordinal SCI scores were used to
address injury severity at study entry, day 3 post-treatment, and
day 42 post-treatment. In both scoring systems, dogs were
considered ambulatory if they could spontaneously rise, bear
weight, and take at least 10 steps without falling. Dogs that were
non-ambulatory had pelvic limb movement evaluated using tail
support. Postural responses were evaluated by placing the dorsum
of the pes on a non-slick surface while manually supporting the
animal and waiting for limb correction. Pelvic limb deep and
superficial nociception were evaluated by applying hemostats to a
nail-bed or interdigital webbing, respectively and evaluating for
the presence of a behavioral or physiological response.
A modified Frankel scale (MFS) was developed to broadly
parallel the American Spinal Cord Injury Association Impairment
Scale (AIS) [15,29]. Dogs were scored as paraplegic with absent
deep nociception (0; equivalent to AIS A), paraplegic with absent
superficial nociception (1; equivalent to AIS B), paraplegic with
intact nociception (2; equivalent to AIS B), or non-ambulatory
with identifiable pelvic limb movement (3; equivalent to AIS C).
The MFS was not a primary trial outcome, but instead was used to
describe the baseline population (overall and by treatment group)
and to stratify the study population for analysis.
The Texas Spinal Cord Injury Score (TSCIS) was used to assess
pelvic limb gait, posture and nociception. This is a more refined
scale than the MFS [15] with a larger array of sub-categories,
including gait assessment that parallels the Basso, Beattie,
Bresnahan Scale [34]. The TSCIS gait score ranges from 0 to 6
in each pelvic limb and correlates to the degree of limb protraction
and weight bearing. The gait classifications include: no voluntary
movement seen when the dog is supported (score = 0); intact limb
protraction with no ground clearance (1); intact limb protraction
with inconsistent ground clearance (2); intact protraction with
ground clearance .75% of steps (3); ambulatory with consistent
ground clearance and significant paresis-ataxia that results in
occasional falling (4); ambulatory with consistent ground clearance
and mild paresis-ataxia that does not result in falling (5); and
normal gait (6). Pelvic limb postural responses using the TSCIS
were scored in each limb as absent (0), delayed (1, correction
occurred .1 second after positioning), and present (2). Nocicep-
tion was scored in each limb as absent (0), deep nociception only
present (1), or both deep and superficial nociception present (2).
Magnetic Resonance Imaging (MRI)
Vertebral column MRI was performed on enrolled dogs, except
in cases where animals were evaluated outside of normal operating
hours or the scanner was unavailable due to mechanical failure.
Between September 2008 and July 2011, a 1.0 T system (Siemens
Magnetom, Malvern, PA) was utilized to acquire images; for the
remainder of the trial images were generated using a 3.0 T MRI
MMP Inhibition in Spinal Cord Injured Dogs
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(Simens Verio, Malvern, PA). Dogs that received MRI had sagittal
T2-weighted (T2W) images reviewed by 1 investigator (JML) using
commercially available software (eFILM, Merge Healthcare,
Chicago, IL) prior to un-blinding. The acquisition parameters
for sagittal T2W images generated at 1T and 3T included a
repetition time of 3500 ms, echo time of 90 ms, and slice thickness
of 2.0 mm. The presence of spinal cord T2W hyperintensity was
determined by visually comparing injured parenchyma to
surrounding spinal cord. This technique has been used extensively
in human and canine MRI studies and produces repeatable results
that correlate with behavioral measures of SCI severity and
recovery [35,36].
MMP-2/MMP-9 Activity in CSF and Serum
CSF and serum samples (n = 16/treatment group) were
randomly selected at the end of the trial by computerized sorting
on random numbers. Purpose-bred Beagle dogs (n = 5) were
sampled as controls. Serum samples with overt hemolysis were
excluded from analysis.
Activity of MMP-2 and MMP-9 in serum and CSF samples was
assessed in a blinded manner using a previously developed
electrophoretic method [37–39] that included a synthetic peptide
(AAPPtec, Louisville, KY) (sequence: Ac-NGDPVGLTAGAGK-
NH2), tagged with a fluorophore BODIPY-FL-SE (Invitrogen,
Carlsbad, CA). The substrate was mixed with either serum or
CSF, with phosphate buffered saline as the negative control. After
reacting for 1 hour, aliquots were loaded onto 20% polyacryl-
amide gels and the samples were electrophoresed. Gels were
imaged using a BioDoc-It M-26 transilluminator (UVP, Upland,
CA, USA). The image was scanned in a Storm 840 workstation
(Molecular Dynamics, Sunnyvale, CA, USA) with ImageQuant
v5.2 software and fluorescent signal was quantified using ImageJ
(1.440, National Institutes of Health, Bethesda, MD).
To assess ability of GM6001 to inhibit MMP-9, activity
(described above) was determined using human recombinant
MMP-9 (Sigma, St. Louis, MO) that was serially diluted in DMSO
to final concentrations of 0.01 mM to 200 mM. Controls consisted
of enzyme and substrate only and substrate and GM6001 only.
Statistical Analyses
Noncompartmental pharmacokinetic analysis was performed
(Phoenix WinNonLin 6.3, Pharsight, St. Louis, MO), and
estimates of the parameters of Tmax, Cmax, T1/2, and area
AUC0-obs and AUC0-‘ were calculated for the single dose.
Activities of MMP-2/MMP-9 in CSF and serum were
compared between healthy control dogs and the dogs with SCI
using the Wilcoxon rank-sum test. The Wilcoxon rank-sum test
was also used to compare CSF and serum MMP-2/MMP-9
activities between dogs with and without selected characteristics
that were potential modifiers of MMP-2/MMP-9 (i.e., age, breed,
sex, and markers of disease duration or severity). To compare
serum MMP-2/MMP-9 values among treatment groups, the
serum MMP-2/MMP-9 activities were converted to ranks, and the
ranks were compared using a generalized linear model; multiple
pair-wise comparisons between treatments were made using the
method of Sidak. Model fit was assessed graphically using
diagnostic plots of residuals.
For the clinical trial data, a strategy for analysis of data was
developed a priori, including our decision to stratify the population
based on SCI severity at admission. Baseline characteristics were
compared among the 3 treatment groups to determine whether
there was any evidence of differences among groups. Categorical
variables were compared using chi-squared analysis and contin-
uous or ordinal variables were compared using Kruskal-Wallis
tests. The primary outcome for the trial was the TSCIS score on
day 42. The TSCIS on day 3 was considered a secondary
outcome. The association of TSCIS with treatment group and
other individual variables was assessed using generalized linear
modeling. Individual variables significantly associated with TSCIS
were analyzed using multivariable generalized linear modeling
using maximum likelihood estimating methods. Multiple compar-
isons among groups were adjusted using the method of Sidak.
Model fit was assessed graphically using diagnostic plots of
residuals. Comparisons of proportions among treatments groups
(e.g., frequency of adverse events) were made using chi-squared or,
when appropriate, Fisher’s exact tests. Significance was set at P,
0.05 for all analyses. Analyses were performed using S-PLUS
statistical software (Version 8.2, TIBCO, Inc., Seattle, WA).
Results
GM6001 is Well Tolerated in Naive Dogs
We first addressed the safety of GM6001 using a dose tolerance
study. Four healthy dogs were randomized to receive DMSO
vehicle, 100 mg/kg GM6001, 150 mg/kg GM6001, or 300 mg/
kg GM6001 SC every 12 hours for 3 days. Following drug
delivery, all studied parameters were within normal limits, with the
following exceptions: 1) increase in body temperature in all
GM6001-treated dogs which peaked 6 days after treatment was
completed (Fig. S1); 2) transient decrease in food consumption
during the 3 days of drug delivery (mean percentage of food
consumed, 64.5% 612.9%) in comparison to the 3 days following
delivery (mean percentage of food consumed, 91.7% 616.3%);
and 3) the presence of subcutaneous nodules at the drug delivery
sites that regressed in size following delivery in all animals (Fig.
S2). No lesions were detected via necropsy or histopathology in the
dog that received vehicle. In the dog receiving 300 mg/kg
GM6001 twice daily for 3 days, sites of subcutaneous drug
deposition were surrounded by a connective tissue capsule with
minimal inflammation; additionally, there was mild bile duct
hyperplasia. The absence of substantial adverse events in this
tolerance study suggested that GM6001 would have an acceptable
safety profile in injured dogs.
GM6001 is Rapidly Detected in Plasma After
Subcutaneous Administration
As the PK of GM6001 might differ from that in rodent [40], we
determined the PK in normal dogs. GM6001, administered once
at 100 mg/kg SC, was detected in plasma at 5 minutes in all dogs,
with a mean time to peak concentration (Tmax) of 0.7 hours (S.D.
61.3 hours) (Fig. 1). The mean peak concentration (Cmax) was
1370 ng/mL (S.D. 6361 ng/mL), mean apparent elimination
half-life (T1/2) was 524 hours (S.D. 6428 hours), and the mean
plasma concentration of GM6001 at 96 hours was 80 ng/mL
(S.D. 620 ng/mL). Mean area under the curve (AUC) from time
0 to last observed concentration (AUC0-obs ) (16,100 hr*ng/mL
62981) and mean AUC from time 0 to infinity (AUC0-‘ )
(58,225 hr*ng/mL 637,054) resulted in an extrapolated percent-
age of AUC of 65%. The only notable adverse event was the
presence of focal subcutaneous nodules that regressed with time.
The GM6001 utilized in the clinical trial had marked in vitro
MMP-9 inhibition at concentrations approximating those
achieved in dog plasma 96 hours post-drug delivery (Fig. 2). As
the objective was to target the acutely injured cord, we selected a
single 100 mg/kg SC dose of GM6001 in dogs to achieve plasma
drug concentrations which would peak almost immediately after
delivery and be sustained at levels sufficient to inhibit MMPs
in vitro for at least 96 hours following delivery.
MMP Inhibition in Spinal Cord Injured Dogs
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Clinical Trial Enrollment
Enrolled dogs were randomized to a saline placebo group
(n = 38 dogs), a DMSO group (n = 37), and a GM6001 group
(n = 33) (Fig. 3). Three dogs were euthanized prior to discharge
from the hospital due to neurologic deterioration and 17 dogs did
not return for 42-day follow-up examination. Of critical impor-
tance, there were no differences in baseline population character-
istics such as breed, gender, or injury level among treatment
groups, indicating that confounding based on these parameters
was unlikely (Table 1).
Adverse Events in Spinal Cord Injured Dogs
Adverse events were recorded during hospitalization and were
classified as fever, gastrointestinal, injection site, urinary, or other
(Table S1). A significantly greater number of dogs in the GM6001
group had injection site reactions (45%; 15/33) relative to either
the saline control dogs (5%; 2/38) or DMSO dogs (0%; 0/36) (P,
0.0001; Kruskal-Wallis test). These reactions were transient and
consisted of focal dermal and subcutaneous swelling.
Increased MRI T2W Signal within the Spinal Cord is
Associated with Poor Recovery
Vertebral column MRI was performed on 76/107 dogs enrolled
in the clinical trial. In all cases, spinal cord compression associated
with IVDH was identified with variable presence of increased
T2W signal (27/76 dogs) within the spinal cord (Fig. 4). High
spinal cord T2 signal, suggestive of contusion, was significantly
more common in dogs with severe SCIs (MFS= 0; 11/13)
compared with those with mild-to-moderate SCIs (MFS.0; 16/
63) (P = 0.0001; Fisher’s exact test). Dogs with increased T2W
spinal cord also had significantly (P,0.0001; generalized linear
model) poorer recovery of function 42 days following SCI
(estimated TSCIS 9, 95% CI 7–12) compared to dogs with
normal spinal cord T2W signal (estimated TSCIS 15, 95% CI 14–
17). The presence of compressive SCI with variable presence of
T2W hyperintensity in the spinal cord parallels what is found on
MRI in humans with traumatic myelopathy, including relation-
ships between function and spinal cord T2 signal [36].
Characterization of Cells in CSF Following Spinal Cord
Injury
CSF was acquired immediately prior to drug or placebo
delivery in 102/107 (95%) clinical trial dogs; all 5 un-injured
control animals also had CSF collected. Total nucleated cell count
was significantly (P = 0.0034, Wilcoxon rank-sum test) higher in
SCI dogs (median = 3 cells/mL, range 0–71) compared with
control dogs (median= 0 cells/mL, range 0–1). Amongst dogs with
CSF pleocytosis (total nucleated cell count .5 cells/mL),
neutrophils were most frequently identified (median 43%, range
2–89%), followed by mononuclear cells (median 25%, range 6–
95%) and lymphocytes (median 18%, range 4–70%). CSF red
blood cell count was likewise significantly (P = 0.0022, Wilcoxon
rank-sum test) increased in dogs with SCI (median 48 cells/mL,
range 0–15,040). Together, these findings support a pro-inflam-
matory state in the acutely injured canine spinal cord.
Figure 1. Pharmacokinetics of GM6001 in dogs. Administration of a single 100 mg/kg subcutaneous dose of GM6001 to dogs resulted in the
rapid development of peak plasma drug concentrations with drug still detectable 96 hours post-delivery. Administration of a second dose of GM6001
to a sub-group of dogs 12 hours following initial drug delivery resulted in increased plasma drug concentrations at all assessed time points.
doi:10.1371/journal.pone.0096408.g001
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GM6001 Reduces Gelatinase Activity in Serum of Spinal
Cord Injured Dogs
We utilized a fluorescent electrophoretic technique to determine
if MMP-2/MMP-9 activity increases in CSF and serum in dogs
with SCI and whether activity is reduced after treatment [37–39].
MMP-2/MMP-9 activity in the CSF did not differ between dogs
with SCI and control dogs (P = 0.5011; Wilcoxon rank-sum test)
(Table S2, Fig. S3). Dogs with SCI had significantly (P = 0.0128;
Wilcoxon rank-sum test) higher serum MMP-2/MMP-9 activity
prior to treatment compared with control dogs, but activity did not
vary based on clinical factors or MRI features of SCI (Table 2,
Fig. 5). Serum MMP-2/MMP-9 activity was significantly (P,0.05;
generalized linear model) lower in dogs receiving GM6001 3 days
following treatment compared to dogs receiving either DSMO or
saline (Fig. 6). Thus, these findings confirm the effectiveness of
GM6001 in reducing the abnormal elevation of MMP-2/MMP-9
in serum of spinal cord injured dogs.
DMSO Enhances Recovery in Dogs with Severe Spinal
Cord Injuries
In dogs with mild-to-moderate SCI (i.e., MFS .0), there was
robust recovery of function by 42 days with 64 of 71 (90%) dogs
independently walking and 69 of 71 (97%) having intact pelvic
limb nociception. Treatment group did not influence 3 or 42 day
TSCIS (Fig. 7, Fig. S4). Dogs with mild-to-moderate SCI had
significantly higher 42-day TSCIS (mean 15; 95% CI 12–18)
compared to those with severe SCI (mean 7; 95% CI 4–9) (P,
0.0010; generalized linear model).
In dogs with severe SCI (i.e., MFS= 0), those receiving either
DMSO or GM6001 had significantly (P,0.05; generalized linear
model) more robust functional recovery compared with those
receiving saline placebo (Fig. 7) at 42 days. Sub-components of the
42-day TSCIS were examined in dogs with severe SCI to better
capture the influence of treatment on motor, sensory, and postural
recovery. Sensory and postural scores did not differ significantly
between treatment groups. Dogs receiving saline had an estimated
mean motor score of 2 (95% CI 0–4.0) (suggesting absent to
minimal pelvic limb movement with tail support) that was
significantly (P,0.05; generalized linear model) less than the
estimated mean motor score for dogs receiving DMSO (mean, 5;
95% CI 2.0–8.0) or GM6001 (mean, 5; 95% CI 2.0–8.0) (Fig. 8).
The distribution of motor scores for both the DMSO and
GM6001 treated dogs indicated that the majority of animals in
these groups developed coordinated stepping movements with tail
support and of those regaining movement many (6 of 12; 50%)
walked without any support. Dogs that were treated with DMSO
or GM6001 that regained pelvic limb movement typically (10 of
12; 83%) also recovered limb nociception. The extent of
neurological recovery at 42 days post-injury was not significantly
different in DMSO- and GM6001 (dissolved in DMSO)-treated
groups. Such findings suggest that DMSO, rather than GM6001
contributed to enhanced recovery in these treatment groups.
Discussion
This study was designed as a large-scale clinical trial to evaluate
MMP inhibition in a clinically relevant, naturally occurring canine
SCI model. Using advanced technology to measure activity of
MMP-2/MMP-9, we show that these proteases are elevated in
serum of dogs across all levels of injury severity and that GM001,
given as a single bolus subcutaneously, significantly reduced this
activity. Despite the effectiveness of GM6001 in targeting early
MMP activity, both GM6001, solubilized in DMSO, and DMSO
Figure 2. In vitro inhibition of MMP-9 by GM6001. Calibrated MMP-9 activity (Log 106), as measured by a fluorescent electrophoretic technique,
was dramatically attenuated by GM6001 in vitro at various concentrations. Plasma concentrations of GM6001, measured 96 hours following a single
100 mg/kg subcutaenous dose (range 0.162.26 mM or 60–100 ng/mL), approximated those needed in vitro to robustly inhibit MMP-9 (0.2 mM or
77 ng/mL). Groups marked with an asterisk (*) had significantly (P,0.05) different calibrated MMP-9 activity from reference (no GM6001) using a one
tailed Student’s t-test.
doi:10.1371/journal.pone.0096408.g002
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alone produced similar levels of neurological improvement in dogs
with severe SCIs, relative to saline controls. At 42 days post-injury,
these dogs showed robust stepping movements that were visible
with tail support and many independently ambulated; saline-
treated dogs either showed no movement or had minimal limb
advancement without stepping. Together, these findings demon-
strate that early blockade of MMPs did not improve long-term
neurological recovery. Rather, DMSO alone was responsible for
the beneficial outcomes in dogs with severe SCIs.
The clinical trial described here was designed to include dogs
with both severe (paraplegia and absent nociception) and mild-to-
moderate SCIs (non-ambulatory with intact nociception) for
several reasons. First, there is an abnormal elevation of MMP-9
in serum [20], CSF [20,41] and spinal cords of dogs [42] with
IVDH across a spectrum of injury severities. Second, while long-
term recovery of ambulation is common (64 of 71 dogs in this trial
walked independently) in the mild-to-moderate injury group, few
animals normalize with reference to motor or postural scores [43].
Thus, there is an opportunity, even within animals that are likely
to show marked recovery, to examine the effect of therapeutics.
We chose to stratify our population based on SCI severity to
examine the effect of treatment on neurologic recovery. This
approach was necessary given the well-known difference in
outcome between these populations (approximately 85–95% of
mildly-to-moderately and 50–60% of severely injured dogs recover
independent ambulation) and the potential for differential
activation of secondary injury pathways based on SCI severity
[30–33]. Stratification based on SCI severity is common and
accepted in human clinical trials because of expected differences in
recovery between injury groups and the potential impact of this
difference on evaluation of effectiveness of therapies [44,45].
GM6001 is a broad-spectrum MMP inhibitor that has been
shown to exert neuroprotection in rodent models of brain and
SCIs, primarily via antagonism of MMP-9 associated with
neutrophils [1]. Evidence supporting this position includes a
temporal association between neutrophil trafficking and MMP-9
Figure 3. Consolidated Standards of Reporting Trials (CONSORT) Diagram. Flow diagram depicting progress through different phases of
the clinical trial including enrollment, group allocation, and follow-up.
doi:10.1371/journal.pone.0096408.g003
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expression, reduced expression of MMP-9 in spinal cord injured
mice that are neutrophil-depleted, and reduced neutrophil content
within injured spinal cords of MMP-9 null mice [2,8,46]. In this
study, GM6001 was delivered SC using DMSO as a vehicle.
While the high prevalence of injection site reactions and route of
administration may have altered drug absorption in comparison to
Figure 4. T2-weighted magnetic resonance images in dogs with spinal cord injuries from intervertebral disk herniation. In 1 dog (A,
B) that was non-ambulatory with intact pelvic limb movement and sensation, there was focal ventrolateral spinal cord compression at the T12-T13
vertebral articulation without spinal cord signal change. A second dog (C, D) with paraplegia and absent pelvic limb deep nociception had
compression at the T12-T13 vertebral articulation. There was extensive spinal cord T2-weighted hyperintensity (white arrows) visible on the sagittal
image (C), suggestive of processes seen in contusion injuries such as edema, necrosis, hemorrhage, or cellular infiltrates. The transverse image (D,
level of T13 vertebral body) indicated that T2-weighted hyperintensity was predominantly localized to the gray matter.
doi:10.1371/journal.pone.0096408.g004
Figure 5. Serum MMP-2/MMP-9 activity in healthy and injured dogs. Box-and-whisker plots summarizing the distribution of MMP 2/9
activity for healthy control dogs (N= 5) and dogs with spinal cord injury (SCI; N = 42) that had serum collected. Values of serum MMP 2/9 activities
were significantly (P = 0.0128) greater for dogs with SCI included in the trial than control dogs. The horizontal lines with triangles represent the
median value; the horizontal lines at the bottom and top of the boxes represent the 25th and 75th percentiles of the data, respectively. The thin
vertical lines extending up or down from the boxes to horizontal lines (so-called whiskers) extend to a multiple of 1.756 the distance of the upper
and lower quartile, respectively. Horizontal lines with circles represent values outside the limits of the whiskers.
doi:10.1371/journal.pone.0096408.g005
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studies in other species, our data support favorable PK via SC
administration of GM6001. Furthermore, relatively small plasma
concentrations of GM6001 present 3 days post-delivery appear
capable of modulating MMP-2/MMP-9 activity in study dogs.
Here we studied the effects of GM6001 on MMP-2/MMP-9
activity in serum. While there was no relationship between injury
severity and level of MMP-2/9 activity in serum, spinal cord
injured dogs showed an increase in these proteases relative to
healthy controls. Moreover, the early elevation of serum MMP-2/
MMP-9 activity was significantly reduced following treatment with
GM6001, a finding which serves to confirm the effectiveness of the
drug in reducing proteolytic activity.
While MMP-2/MMP-9 activity was detected in the CSF of
injured dogs, activity did not differ between healthy control dogs
and those with SCI. The lack of a demonstrable difference in CSF
MMP-2/MMP-9 between SCI and control groups may reflect the
inability of this assay to distinguish between the 2 proteases. Based
upon an earlier study using gelatin zymography [20], MMP-2 was
found to be expressed in the CSF of normal dogs and remained
unchanged after SCI. In contrast, MMP-9 was only detected in
Figure 6. Serum MMP-2/MMP-9 activity pre- and post-drug delivery. Dogs were first randomized into 3 treatment groups, and serum was
obtained prior to administration of saline, DMSO, or GM6001 (panel A). There were no differences in serum MMP-2/MMP-9 activity among treatment
groups at the time of admission (panel A); however, at day 3, there was a significant (P = 0.0482) difference in serum activity between GM6001-treated
dogs and the other treatment groups (panel B). See Figure 5 for a description of box-and-whisker plots. Groups marked with different letters differ
significantly (P,0.05).
doi:10.1371/journal.pone.0096408.g006
Table 2. Values of serum MMP-2/MMP-9 activity were not significantly associated with various clinical variables.
Variable Median (Range) of MMP-2/MMP-9 Activity in Serum P value
Age #5 Years (N = 28) .5 Years (N = 12)
1,519,998 (1,009,205–3,708,449) 1,315,180 (769,191–2,700,981 0.1458
Sex Male (N= 22) Female (N= 18)
1,504,968 (1,009,205–3,708,449) 1,455,587 (769,191–2,700,981) 0.2625
Neutered Not neutered (N =9) Neutered (N= 31)
1,492,947 (1,009,205–2,266,638) 1,479,017 (769,191–3,708,449) 0.5881
Breed Dachshund (N=28) Other (N =12)
1,411,546 (769,191 - 3,144,395) 1,528,755 (941,766 - 3,708,449) 0.4932
Chondrodysplastic Yes (N= 38) Other (N =2)
1,474,618 (769,191–3,708,449) 1,983,362 (1,975,379–1,991,345) 0.2564
Duration of clinical signs prior to admission #12 hours (N= 12) .12 hours (N= 28)
1,453,961 (1,009,205 - 3,708,449) 1,485,982 (769,191–3,144,395) 0.9189
#24 hours (N= 35) .24 hours (N= 5)
1,492,947 (941,766–3,708,449) 1,310,144 (769,191–2,306,259) 0.5243
T2-weighted hyperintensity Absent (N= 20) Present (N= 11)
1,507,977 (769,191–3,708,449) 1,523,790 (1,062,500–3,144,395) 0.6995
MFS at admission #2 (N= 22) .2 (N= 18)
1,455,587 (1,009,205 - 2,292,539) 1,504,968 (769,191–3,708,449) 0.4924
Medians (and ranges) and P values derived from Wilcoxon-rank sum tests are reported for the categorical variables listed above. MMP=matrix metalloproteinase;
MFS =Modified Frankel Score.
doi:10.1371/journal.pone.0096408.t002
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spinal cord injured dogs [20,41]. Thus, in the current study, the
absence of any differences between injured and control dogs may
have been confounded by the constitutive activity of MMP-2 in
CSF that may have masked any increase in MMP-9.
There are likely a number of possible explanations for why
GM6001 failed to improve neurological recovery in spinal cord
injured dogs. First, while GM6001 has been shown to improve
neurological outcomes in various rodent models of brain and
spinal cord injury [2,47,48], no studies to date have evaluated
efficacy in dogs. Thus, there may be species differences in
responsiveness to GM6001 and/or MMP-directed pathogenesis.
Additionally, effects of GM6001 demonstrated in rodents may not
Figure 7. Evaluation of primary outcome in dogs with SCI. Box-and-whisker plots of TSCIS on day 42 by treatment group, stratified by MFS at
admission (MFS= 0, left panel; or MFS .0, right panel). There were no significant differences in TSCIS among dogs with MFS score .0 (right panel),
but TSCIS was significantly (P,0.05) greater for the GM6001 and the DMSO group than saline treated dogs with MFS= 0 (left panel). See Figure 5 for a
description of box-and-whisker plots. Groups marked with different letters differ significantly (P,0.05).
doi:10.1371/journal.pone.0096408.g007
Figure 8. Evaluation of TSCIS motor score at day 42 following SCI. Box-and-whisker plots of TSCIS motor score on day 42 by treatment
group, stratified by MFS at admission (MFS= 0, left panel; or MFS .0, right panel). There were no significant differences in motor score among dogs
with MFS .0 (right panel), but motor score was significantly (P,0.05) greater for the GM6001 and the DMSO group than saline treated dogs with
MFS= 0 (left panel). See Figure 5 for a description of box-and-whisker plots. Groups marked with different letters differ significantly (P,0.05).
doi:10.1371/journal.pone.0096408.g008
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be sufficiently robust to positively influence outcome under the
clinical conditions of this study [49,50]. Second, the drug was
active beyond the first several days post-injury and as such could
have interfered with mechanisms underlying recovery in SCI.
Pharmacokinetics in healthy dogs demonstrated that plasma
concentration of GM6001, present at even the 96-hour time-
point, approximated or exceeded that necessary to block MMP-9
in vitro. As some MMPs modulate the formation of a glial scar and
axonal plasticity [4], their subacute/chronic blockade may result
in adverse neurological outcomes. Third, the timing between SCI
and administration of GM6001 may not have been optimal. The
strong association between MMP-9 expression and neutrophils
suggests that an optimal therapeutic window for GM6001 is
defined by the early trafficking of neutrophils into the injured cord.
Such a position is supported by evidence of pronounced
neurological recovery when the drug was given beginning 3 hours
post-injury in a murine model of SCI [2]. In dogs treated with
GM6001, median delay between injury and enrollment was 12
hours, which may have exceeded the window of efficacy for
GM6001. Finally, while the use of dogs with thoracic and lumbar
spinal cord lesions could have influenced our ability to detect drug-
related effects [51], the proportion of dogs with lumbar lesions was
similar amongst treatment groups (Table 1). Additionally, the
inclusion of lesion location (lumbar versus thoracic) in multivar-
iable generalized linear modeling did not alter the significance or
magnitude of observed treatment effects (data not shown).
We found that DMSO improved motor recovery in dogs with
severe SCIs. This finding is perhaps not too surprising as DMSO,
under defined dosing conditions, has the ability to function as a
neuroprotectant [14] and in some cases when used as a vehicle,
may be synergistic. In the setting of neurotrauma, neuroprotection
is exemplified in a study by Di Giorgio et al [52] which compared
the antioxidant curcumin, a-tocopherol, DMSO and saline in a
model of traumatic brain injury. These authors reported similar
levels of early neuroprotection across all agents relative to the
saline control group. Beneficial effects of DMSO might also be
indicated in studies where DMSO is used as a vehicle without any
additional negative control group. For example, in a recent study
the efficacy of an epidermal growth factor receptor inhibitor was
assessed in a rodent model of SCI [53]. This inhibitor was
compared against its vehicle, DMSO. Recovery of motor and
bladder function was significantly greater in rats that received
DMSO relative to the inhibitor. The authors concluded that the
receptor inhibitor showed no efficacy relative to the ‘‘baseline’’
values as defined by DMSO. Based upon our study, an alternative
explanation is that DMSO did not serve as the ‘‘baseline’’ but
rather may have exerted a beneficial effect. Finally, DMSO, when
co-administered with a candidate therapeutic, offers potential for
synergism, by acting through separate and/or overlapping
pathways. While we found no evidence of this in the current
study, others have reported synergism in a model of brain ischemia
where DMSO was either combined with fructose 1,6-dispho-
sphate, an intermediate of anaerobic metabolism, or prostacyclin
(PGI2) which blocks aggregation of platelets and functions as a
vasodilator [12,54].
The mechanisms underlying DMSO-mediated neuroprotection
have been attributed to its ability to function as a free radical
scavenger and suppress a variety of pathobiologic events including
inflammation, calcium influx, and glutamate excitoxicity [14].
Such broad-based, temporally-defined targets may account for the
extended window of efficacy (within 48 hours of injury) in spinal
cord-injured dogs.
Dogs with severe SCIs and treated with either DMSO or
GM6001 in DMSO showed a consistent (.80%), improvement in
pelvic limb stepping. A critical question is whether this stepping
was voluntary or mediated through the central pattern generator
(i.e., spinal stepping). The vast majority of these dogs with motor
recovery also regained pelvic limb nociception (10 of 12; 83%) and
50% walked independently (without tail support) when evaluated
at 42 days post injury. These data would argue that pelvic limb
movement was indeed voluntary in the majority of dogs with
severe SCIs treated with either DMSO or GM6001.
In summary, while this study and others [12,13,52,54]
underscore the potential utility of DMSO for the treatment of
brain and SCI, there remain conflicting reports about the efficacy
of DMSO. This is illustrated in recent studies reporting either no
effects or reduced performance on behavioral tests after traumatic
brain injury [55] and others suggesting improved learning ability
in cerebellar mutant Lurcher mice [56]. As it is shrouded in
controversy as a therapeutic yet commonly used as a vehicle, there
is a need to rigorously evaluate DMSO from the standpoint of
safety, dosing, and efficacy. Given that it is a common vehicle for
drug delivery, there is opportunity to evaluate its synergistic
properties. Such logic has been successfully applied to the
treatment of human interstitial cystitis, where DMSO is given as
part of multimodal regimen [57]. With FDA approval for the
treatment of interstitial cystitis, there is potential for the
repurposing of DMSO, capitalizing on its favorable properties as
a solvent, in developing combinatorial therapies for SCI. The
current study suggests that DMSO has an extended therapeutic
window (up to 48 hours). As time to treatment for human SCI may
be delayed for up to 1 to 3 days post-injury [58], a broader
therapeutic window could potentially expand the population of
spinal cord injured patients that would otherwise not qualify for
treatments with more restricted windows of intervention.
Supporting Information
Figure S1 Rectal body temperature in healthy dogs delivered
DMSO or GM6001. All dogs delivered GM6001 at 6–18 times
the cumulative clinical trial dose (100–300 mg/kg six times)
experienced body temperature elevations beyond normal. The
elevation in body temperature qualitatively appeared greatest in
dogs receiving higher doses of GM6001.
(TIF)
Figure S2 Drug delivery site diameters in healthy dogs receiving
GM6001. Delivery site diameter appeared greatest one day after
administration (panel A) and diminished by day 8 post-
administration (panel B) in dogs receiving 6–18 times the
cumulative clinical trial dose of GM6001.
(TIF)
Figure S3 Cerebrospinal fluid MMP-2/MMP-9 activity in
healthy and spinal cord injured dogs. Although MMP-2/MMP-9
activity tended to be higher in dogs with spinal cord injuries
(n = 40) than healthy controls (n = 5), the difference was not
significant (P = 0.5011; Wilcoxon rank-sum test).
(TIF)
Figure S4 Texas Spinal Cord Injury Score (TSCIS) on day 3
following spinal cord injury. There were no significant differences
in TSCIS based on treatment group for dogs with severe
(MFS= 0) and mild-to-moderate (MFS .0) spinal cord injuries.
Box-and-Whiskers with different letters differ significantly (P,
0.05).
(TIF)
Table S1 Frequency of adverse events and survival (died or
euthanized) by treatment group. Injection site reactions were
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significantly associated with GM6001 delivery, but no other
adverse events were significantly associated with treatments.
(DOCX)
Table S2 Cerebrospinal MMP-2/MMP-9 activity in dogs with
spinal cord injury. Cerebrospinal fluid MMP-2/MMP-9 activity in
dogs with spinal cord injury was not significantly associated with
signalment, duration of clinical signs, or MFS at the time of
admission. Medians (and ranges) and P values derived from
Wilcoxon-rank sum tests were reported for the categorical
variables.
(DOCX)
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